L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment

Osimertinib, a mutant-specific third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is emerging as the preferred first-line of treatment for EGFR-mutant lung cancer. However, osimertinib resistance inevitably develops among patients treated with the drug. The mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meihui, Qin, Jing, Xie, Fajun, Gong, Lei, Han, Na, Lu, Hongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363540/
https://www.ncbi.nlm.nih.gov/pubmed/35943592
http://dx.doi.org/10.1007/s12672-022-00537-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363540/
https://www.ncbi.nlm.nih.gov/pubmed/35943592
http://dx.doi.org/10.1007/s12672-022-00537-7

Ejemplares similares